Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Research & Development: د.إ11 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADX:JULPHAR Gulf Pharmaceutical Industries PSC ADX:JULPHAR
54 GF Score
Price د.إ1.04
GF Value د.إ1.09
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gulf Pharmaceutical Industries PSC Research & Development?

Gulf Pharmaceutical Industries PSC ADX:JULPHAR +0.97% 54 Research & Development is د.إ11 Mil as of Mar. 2026. GuruFocus rates ADX:JULPHAR with a GF Score™ of 54/100 and a GF Value™ of د.إ1.09 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Gulf Pharmaceutical Industries PSC's Research & Development for the three months ended in Mar. 2026 was د.إ5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was د.إ11 Mil.

Gulf Pharmaceutical Industries PSC  (ADX:JULPHAR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Gulf Pharmaceutical Industries PSC Research & Development Related Terms

Gulf Pharmaceutical Industries PSC Research & Development Historical Data

* Premium members only.

The historical data trend for Gulf Pharmaceutical Industries PSC's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gulf Pharmaceutical Industries PSC Research & Development Chart

Gulf Pharmaceutical Industries PSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.20 20.70 19.40 24.50 28.20

Gulf Pharmaceutical Industries PSC Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.40 6.20 0.00 0.00 5.20
ADX:JULPHAR
54GF Score
Gulf Pharmaceutical Industries PSC ADX:JULPHAR
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gulf Pharmaceutical Industries PSC Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was د.إ11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of د.إ11 Mil mean?
Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) has a Research & Development of د.إ11 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Gulf Pharmaceutical Industries PSC and its competitors.
Is Gulf Pharmaceutical Industries PSC's Research & Development too high?
Gulf Pharmaceutical Industries PSC's current Research & Development is د.إ11 Mil. Overall, Gulf Pharmaceutical Industries PSC has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gulf Pharmaceutical Industries PSC's Research & Development compare to MCK and CAH?
Gulf Pharmaceutical Industries PSC's Research & Development of د.إ11 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Gulf Pharmaceutical Industries PSC and its competitors. Gulf Pharmaceutical Industries PSC's current Research & Development is د.إ11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gulf Pharmaceutical Industries PSC stock overvalued right now?
Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) is currently considered Fairly Valued. The stock's GF Value™ is د.إ1.09, compared to a current price of د.إ1.04 — trading 4.6% below its estimated fair value. The current Research & Development is د.إ11 Mil. Gulf Pharmaceutical Industries PSC's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Gulf Pharmaceutical Industries PSC (ADX:JULPHAR), the current Research & Development is د.إ11 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gulf Pharmaceutical Industries PSC (ADX:JULPHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Gulf Pharmaceutical Industries PSC stock appears to be undervalued. The current stock price of د.إ1.04 is trading 4.6% below its estimated GF Value™ of د.إ1.09. GuruFocus considers Gulf Pharmaceutical Industries PSC to be Fairly Valued.

Key valuation signals for ADX:JULPHAR:

  • Research & Development: د.إ11 Mil
  • GF Value™: د.إ1.09 vs. price of د.إ1.04 (4.6% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the ADX:JULPHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gulf Pharmaceutical Industries PSC Business Description

Address Airport Road, P.O. Box 997, Digdaga, Ras Al Khaimah, ARE
Gulf Pharmaceutical Industries PSC is in the business of manufacturing and selling medicines, drugs, and various other types of pharmaceutical and medical compounds in addition to cosmetic compounds. The company operates in four segments: Manufacturing, Trading, Investments, and others. The majority of its revenue is generated from the Manufacturing segment. The geographical segments are UAE, Other GCC countries, and Other countries. It derives maximum revenue from UAE. Its business is centered around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products. Its medicines also targets therapeutic segments such as Diabetes, Gastrointestinal Tract (GIT), Respiratory, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Erectile Dysfunction and Others.
54GF Score

Get the complete analysis for ADX:JULPHAR

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

د.إ1.04
Price
د.إ1.09
GF Value